Northwestern Mutual Wealth Management’s Matinas BioPharma MTNB Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12	Buy	+20	New	+$13	﹤0.01%	4057

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Northwestern Mutual Wealth Management's MTNB Position: Q2 2026 in Review

Northwestern Mutual Wealth Management opened a new position in Matinas BioPharma (MTNB) in Q2 2026: 20 shares worth $12. The stake represents ﹤0.01% of the portfolio and ranks #4057 among its holdings.

25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

Northwestern Mutual Wealth Management held 20 shares of Matinas BioPharma worth $12 as of Q2 2026.
Matinas BioPharma was a new Northwestern Mutual Wealth Management position in Q2 2026.
Matinas BioPharma made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #4057 holding.
25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.